Halfway thru the year and we are fast approaching 01 Jan

New Post Public Reply Private Reply Replies (1) Message Board
WBeacham
419
Halfway thru the year and we are fast approaching 01 Jan 2025, the enactment date for the NOPAIN Act. I don’t know what the process is for BIEL to be accepted into the program. I AM sure that there IS a process. I have written extensively on all things BIEL for several years so I leave it up to the reader to re-read should you be so inclined. I don’t offer myself up as an insider or have insider knowledge via secret back channels. I am NOT that guy and have no desire to be that guy. All my comments are my opinion and based on freely available information.

This company is flying under the radar for most people and most investors. There is a reason for this. PEMF, and the products based upon the science, is an anathema to the Rockefeller (nee: Rokkenfelder) based, drugs and surgery only, profit-driven western medicine. Money talks, and more specifically, it shouts and dictates. There is (are?) volumes of material to substantiate the facts. Media plays a huge part. The same people controlling the media are bosom buddies w/ the same pscho-paths who control the medical establishment and, yes, they do, also, control and ‘own’ money. The bumper sticker is: “The Central Problem is Central Banking”. Do your homework. We are all victims of the three M’s: Money, Media, Medical.

I talk to people all the time about Actipatch. I have a first-rate, 5 min. elevator pitch, well -honed over the years. The latest was 3 days ago, details don’t matter. Word of mouth only goes so far. Grassroots activism is ideal but takes time that we don’t have. And thus, it comes round to The NOPAIN Act which is essential to the USA adoption of PEMF as expressed via RecoveryRx, and any & all other products such as a rechargeable device, a surgery incision device, and OA thumb device. The vet/pet product is a stand-alone but potentially large moneymaker.

Oddly enough, the profit-driven mania surrounding current medical practice is the same motivation for adoption of BIEL PEMF products into the mass marketplace via The NOPAIN Act, i.e. - money. Go figure, pun intended. Which, of course, brings us full circle to what preoccupies most investors and message board posters alike, myself included, and that is, a buyout vis-a-vis The NOPAIN Act. This ‘transition’, should it happen, is tantamount to a car entering a ramp going at 10 mph onto an interstate highway and in the very next second is traveling at 68 mph on the interstate highway.

In between 10 and 68 is a full menu of presumptions and improbabilities that take years to come to fruition; lots and lots of dedicated work. BIEL is an outlier until it isn’t. My guess is any announcement would come 'out-of-the-blue’, seemingly, but in reality (if truth be known) has been building a full head of steam for quite awhile, hidden in plain sight. Think of one of those pscho-pictures that are supposed to depict a girl picking flowers in a field when most people only see a bunch of stupid dots that looks like nothing. Imagination plays a part but is it all smoke & mirrors, only wishful thinking on our part?

For a short while I did try to find out what I could about CPT codes being assigned to BIEL and thinking that being the sole prelude to being accepted by CMMS. Naivete personified. What I discovered is mountains of red tape that would dwarf the Alps, the Rockies, the Andes and the Himalayas all rolled into one. The levels of complexity, inter-connectedness of agencies and hundreds of 3 & 4 letter acronyms is mind-boggling; a lawyers’ dream, a layman’s nightmare and a bureaucrat’s fantasyland.

Much has been made of Dr. Koneru and Keith Nalepka leaving the company. Dr. Koneru going to Viant (worldwide medical device maker) and Keith going to VLMS Global Healthcare (medical coding, i.e. - CPT codes). It doesn’t take much ‘imagination’ to see how these ‘departures’ fit into the big picture, if indeed, a big picture exists. I see these ‘departures’ as deploying your assets to make the best use of them. Think in terms of the previous paragraph. Preparing the ‘ramp’ for the ‘out-of-blue’ transition is a massive undertaking. This is my OPINION. DO NOT READ ANYTHING INTO THIS OTHER THAN THAT.

Let’s talk numbers. BIEL has 24 billion shares outstanding. I will presume a buyer pays $0.10 per share which is $2.4 billion dollars. How does one justify that amount in terms of current income of BIEL? In short, you don’t. You look at market potential which is what a buyer does. Large corporations have entire departments devoted exclusively to M&A, Mergers & Acquisitions. SWOT analysis is a common business practice. Do some research on chronic pain, phantom pain sufferers, arthritis, opioid abuse, general pain issues and you will soon see a (USA) market potential in the 100’s of millions pain incidents where most, if not all, can be relieved and/or eliminated through the use of PEMF device such as RecoveryRx, a prescription (a key differentiation) product. We are the drug-free, adverse-event free, side-effect free antidote to Opioid abuse.

Let’s also presume, if accepted thru the The NOPAIN Act, a $20 profit margin on each device. On one veteran-owned website, RecoveryRx is listed for $250. Do the math w/ ‘only’ 50 million units sold annually. That is $1 billion profit meaning in less than 3 years the investment of $2.4 billion has been fully recovered. And here’s the best part - that is recurring profit, year after year … Should BIEL get accepted into CMMS via the NPA then the VA and DOD will follow suit. This is the USA market, excluding Canada, Australia, Europe, Asia and the Middle East.

So, there you have it. Take it or leave it. We, as investors, are never going to get any indications one way or the other. For me, there is no debate. The economic argument of acceptance is painfully (again, pun intended) obvious. To say that NDAs are in effect is an understatement. And even more to the point, if an insignificant message board poster can make the case, then maybe a well-funded, well-trained, ‘plugged-in’ M&A department might be able to???
Quote:
THESE are the times that try men’s souls. The summer soldier and the sunshine patriot will, in this crisis, shrink from the service of their country; but he that stands it now, deserves the love and thanks of man and woman.

Hope for the best, Prepare for the worst. Adapt - Improvise - Overcome

"Sic parvis magma" - Greatness from small beginnings

All the best, WBeacham

P.S. - I have a cat named Andy, named after, and in honor of, Andy Whelan, the Founder of Bioelectronics, maker of Actipatch and RecoveryRx. Andy is a warrior w/ cojones. Andy is a free-range cat in that he is free to go wherever he pleases, whenever he pleases. One night, snowing, wind howling, wind chill at -20 degrees, Andy survived and showed up the next day. He braved the worst and carried on. He’s like that, ya know. We, the investors of BIEL, will carry on in the same tradition. We have braved the worst. Many good people are working on our behalf. I pray for them daily and so should you.

BioElectronics Corporation (BIEL) Stock Research Links

BIEL Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Cloud Software Group's $2B Debt Offer Wraps Up

Updated Category News Views 25

Sizing Up Cloud Software Group’s Recent Maneuver Whoever thought navigating debt was a dull spectacle hasn’t kept up with Cloud Software Group's recent financial theatrics. With a $2 billion cap on the table, their cash tender offer for 9.00% Senior Secured Second Lien Notes due 2029 didn’t just happen; it paraded onto the financial stage and left a noteworthy...

Continue Reading
Pak Mail Expands: Franchisee Adds Location Fast

Updated Category News Views 66

Franchise Growth: Adding Another Brick When's the last time you heard of a franchisee eager enough to nab a second location? Well, that's exactly what's happening with Manny Zussman, who’s decided his Boulder Pak Mail outlet wasn’t keeping him busy enough. This entrepreneurial spirit's on full display as he's launching another Pak Mail over in Westminster, Colorado....

Continue Reading
Laboratoires Pierre Fabre and XtalPi Unite for AI-Driven Drug Hunt

Updated Category News Views 213

An Unexpected Turn in the Drug Discovery Arena It's not every day that you see a historic French pharma powerhouse and a cutting-edge Chinese tech firm join forces. On one side, we've got Laboratoires Pierre Fabre, steeped in the history and nitty-gritty of clinical drug development. On the other, we’ve got XtalPi Holdings Limited (2228.HK), bringing their high-tech AI...

Continue Reading
Huawei's 2026 Leap in Gartner Magic Quadrant Recognition

Updated Category News Views 92

China's Telecom Giant Steps Up Globally Gartner's all about benchmarks and bragging rights in the tech world, and brother, Huawei just grabbed a major piece of that spotlight in 2026. They've snagged a spot in the coveted Leaders Quadrant of the Gartner Magic Quadrant for Infrastructure Platform Consumption Services. Now, why should folks with skin in the game care?...

Continue Reading
WSIB Slashes Registration Time with Guidewire Boost

Updated Category News Views 39

Quick Fix: Streamlining Ontario's Employer Registration Alright, let's cut through the formalities and tell it like it is: Ontario's Workplace Safety and Insurance Board (WSIB) isn't messing around anymore. They've yanked their antiquated paper-laden process into the digital age, slicing the employer registration wait down from an agonizing eight to ten-day ordeal to a...

Continue Reading
E Ink Backs Soofa: A Solar-Powered Signage Game Changer

Updated Category News Views 68

Pioneering a New Era in Community Signage If you ever thought those static community bulletin boards were outdated, you're not alone. E Ink, one of the big players in ePaper technology, has decided to shake things up by investing in Soofa. These folks at Soofa know a thing or two about connecting communities with smart solutions. Their solar-powered kiosks might just be...

Continue Reading
Reindeer Expands With Google Cloud Marketplace Launch

Updated Category News Views 81

Reindeer Rides Google Cloud's Tailwinds Alright, folks, here's a new twist in the world of enterprise AI that's got my eyeballs popped. Reindeer, that plucky outfit from New York and Tel Aviv, has cozied up with Google Cloud in a move that's set to turn heads in the sector. Now, you might hear "agentic AI" and think it's just some fancy jargon, but this is where it gets...

Continue Reading
Telespazio & Rivada Forge Secure Satellite Network

Updated Category News Views 131

Rivada's Outernet: A New Era of Connectivity Forget the terrestrial wires; we're talking about 600 satellites playing a space-age game of telephone. That's Rivada's Outernet for you, an orbital mesh network that's about to upend the very nature of global communications. Telespazio's new partnership with Rivada is like strapping a rocket onto secure connectivity in the...

Continue Reading
Energenesis Tackles Space Anemia with ATP Boost

Updated Category News Views 47

Gearing Up for Space Medicine: Enter Energenesis With the cosmic frontier drawing investor eyes and day-to-day operations inching skyward, here comes Energenesis Biomedical (TWSE: 6657), poking its head into space medicine. This isn’t just another biotech firm looking to throw drugs at terrestrial problems. No, Energenesis shot its shot at TASTI 2026 with its...

Continue Reading
Gold.com Faces Fiduciary Investigation by Levi & Korsinsky

Updated Category News Views 10

Gold.com in Hot Water: What Shareholders Need to Know You ever wonder how firms like Gold.com find themselves in sticky situations before the ink's dry on the quarterly report? Well, strap in because Levi & Korsinsky, LLP is poking around to see if some officers and directors over there have taken a stroll down Breach Avenue. And let me tell you, if you're holding onto...

Continue Reading

Top 5 Most Recently Viewed Articles

Potential Legal Scrutiny for aTyr Pharma: Seeking Justice for Investors

Updated Category News Views 298

Overview of aTyr Pharma, Inc. aTyr Pharma, Inc. is a biotechnology firm devoted to advancing innovative therapies for patients with rare diseases. The company focuses on immunological and neurological disorders, working diligently to bring solutions to underserved markets. As the company navigates through the complexities of drug development, it also faces scrutiny...

Continue Reading
Signs of Needing Home Care: Key Insights from Experts

Updated Category News Views 42

Spotting the Subtle Shifts Navigating the path of aging isn't exactly a walk in the park, and families often find themselves squinting to see the subtle signs that an aging parent might need a little more than just occasional check-ins. We’re not talking dramatic meltdowns here—no, it’s about those creeping changes that sneak in like an old song you haven’t heard...

Continue Reading
UPLIZNA® Receives FDA Approval for Generalized Myasthenia Gravis

Updated Category News Views 164

UPLIZNA® Gains FDA Approval for gMG in Adults UPLIZNA is an innovative new treatment for adults battling generalized myasthenia gravis (gMG), a debilitating autoimmune disorder. This approval, granted by the U.S. Food and Drug Administration (FDA), heralds a new era for gMG patients, providing them with deep and durable control over their symptoms. The most appealing...

Continue Reading
Monster Energy Launches Refreshing Strawberry Shot Variant

Updated Category News Views 254

Monster Energy Unveils Strawberry Shot Monster Energy is thrilled to announce the introduction of Monster Energy Strawberry Shot, set to captivate fans with its unique twist on the classic OG flavor. This new version infuses the iconic energy blend with an enticing hint of strawberry, promoting an enjoyable and refreshing experience. A Fresh Take on a Classic Favorite...

Continue Reading
Cohen & Steers Quarterly Performance Insights and Future Outlook

Updated Category News Views 163

Cohen & Steers Quarterly Performance Insights Cohen & Steers, Inc. (NYSE: CNS) announced its financial outcomes for the recent quarter ending on June 30. This report sheds light on the firm’s commitment to delivering exceptional results in the investment management sector. Understanding the Second Quarter Financials The recent financial report reflects the company’s...

Continue Reading